| RQP74138 | |
| I. Background | |
| CLEC2D (C-type lectin domain family 2 member D) is also known as CLAX, LLT1, OCIL is receptor for KLRB1 that protects target cells against natural killer cell-mediated lysis, inhibits osteoclast formation, inhibits bone resorption and modulates the release of interferon-gamma. It is also a ligand for the human NKR-P1A (CD161) receptor, present on NK cells and T cells. Furthermore, The reference shows the pathway may as a potential immunotherapy targets. | |
| II. Introduction | |
| Expressed gene: | CLEC2D |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | F12K+10%FBS+600ug/ml hygromycin+2ug/ml puromycin |
| Mycoplasma Testing: | Negative |
| Storage: | Liquid nitrogen |
| Application(s): | Functional(Report Gene) Assay |
| III. Representative Data | |
Figure 1. Dose Response of CD161 Blocking Antibody in CD161 Effector Reporter Cells (Clone 8) With CLEC2D aAPC Cells. | |
E-mail：sales@reqbio.com
Add:3rd Floor, No. 6, Lane 222,
Guangdan Road, Pudong New Area,
Shanghai，China
WeChat public account
